Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment
Infertility
About this trial
This is an interventional treatment trial for Infertility focused on measuring corpus luteum rescue, Gonadotropin Releasing Hormone (GnRH agonist), human Chorionic Gonadotropin (hCG), infertility, pregnancy rate
Eligibility Criteria
Inclusion Criteria:
- age >21 and < 38 years old
- polycystic ovarian syndrome
- risk for ovarian hyperstimulation syndrome
Exclusion Criteria:
- recurrent abortion
- endometriosis
- more than 3 IVF failures
- use of oral contraceptive pills in the preceding 3 months
- low response to gonadotropins
Sites / Locations
- Assisted Reproduction Center "Governor Mário Covas" of the Faculty of Medicine of the University of São PauloRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
GnRH agonist
Control
3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.